Originally reported by thelincolnianonline. Read more
Archive summary Clinical & research
Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness
Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia. Phase 3 results highlighted rapid and durable antidepressant effects CEO Kabir Nath said the
Newsletter
The weekly digest
Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.